FDA grants approval for Pfizer’s Prevnar 13 to prevent pneumococcal pneumonia
American pharmaceutical company Pfizer has received the US Food and Drug Administration (FDA) approval for its Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) to prevent pneumonia and other invasive diseases.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Diphtheria | Food and Drug Administration (FDA) | Grants | Meningitis Vaccine | Pfizer | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Vaccines